| 2026-08-11 | Press release | Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update |
| 2026-06-29 | Presentation | Download PDF file, (opens in new window) |
| 2026-06-18 | Press release | Download , Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting, Jun 18, 2026, (opens in new win |
| 2026-06-15 | Press release | Download , Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation a |
| 2026-06-08 | Press release | Download , Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-T |
| 2026-05-29 | Presentation | Download PDF (opens in new window) |
| 2026-05-27 | Press release | Download , Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit, May 27, 2026, (open |
| 2026-05-12 | Press release | Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update |
| 2026-05-12 | Press release | Download , Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrop |
| 2026-05-11 | Presentation | Download PDF (opens in new window) |
| 2026-04-30 | Presentation | Download PDF (opens in new window) |
| 2026-04-09 | Press release | Download
, Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS, Apr 09, 2026, (opens in new window) |
| 2026-04-02 | Press release | Download , Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director |
| 2026-04-01 | Presentation | Download PDF (opens in new window) |
| 2026-03-18 | Press release | Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontot |
| 2026-03-16 | Press release | Download
, Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results, Mar 16, 2026, (opens in new window) |
| 2026-02-27 | Presentation | Download PDF (opens in new window) |
| 2026-02-10 | Press release | Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, |
| 2026-02-02 | Presentation | Download PDF (opens in new window) |
| 2026-01-30 | Press release | Download , Coya Therapeutics Announces $11.1 Million Private Placement, Jan 30, 2026, (opens in new window) |
| 2026-01-20 | Press release | Download
, Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders, Jan 20, 2026, (opens in new window) |
| 2026-01-08 | Press release | Download
, Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients, Jan 08, 2026, (opens in new window) |
| 2026-01-05 | Press release | Download , Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 fo |
| 2025-12-27 | Presentation | Download PDF (opens in new window) |
| 2025-12-23 | Press release | Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 A |
| 2025-12-09 | Press release | Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS |
| 2025-11-25 | Press release | Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences |
| 2025-11-12 | Press release | Download
, Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update, Nov 12, 2025, (opens in new window) |
| 2025-11-04 | Press release | Download
, Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo, Nov 04, 2025, (opens in new window) |
| 2025-10-27 | Press release | Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of |
| 2025-10-24 | Press release | Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock |
| 2025-10-23 | Press release | Coya Therapeutics Announces Proposed Public Offering of Common Stock |
| 2025-10-07 | Press release | Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or M |
| 2025-09-29 | Press release | Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dos |
| 2025-09-22 | Press release | Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in |
| 2025-09-16 | Press release | Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulato |
| 2025-09-04 | Press release | Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial |
| 2025-09-03 | Press release | Coya Therapeutics to Participate at Upcoming September Investor Conferences |
| 2025-08-25 | Press release | Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment |
| 2025-08-12 | Press release | Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update |